News

   

Resolution Therapeutics Announces Upcoming Scientific Presentations at EASL Congress 2024

- Late-breaking abstract on extended follow-up data from…

Resolution Therapeutics to Participate in the Jefferies Global Healthcare Conference

Edinburgh and London, UK, 28 May 2024 – Resolution Therapeutics…

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

STC-15 is the first METTL3 inhibitor to enter clinical development Clinical…

Novo Holdings Boston office named a 2024 Best Place to Work by the Boston Business Journal

Investment firm’s connection to the Novo Nordisk Foundation…

Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024

Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE:…

Delsitech announces a major licensing agreement on drug delivery

Turku, Finland – 23rd May, 2024. Clinical-stage drug delivery…

Bacteria in our gut could play a role in cardiometabolic disease: A new initiative aims to find out

A new Denmark-based research initiative aims to establish a potential…

NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

Additional funding will be used to explore novel biology around…

BaseLaunch announces a new partnership with AbbVie

Media release Basel, Switzerland, 22.05.2024 BaseLaunch announces…

One in three people die due to atherosclerosis: A new initiative aims to find new ways to prevent it

Globally, cardiovascular diseases due to atherosclerosis –…

Novo Holdings to acquire majority stake in Single Use Support

Novo Holdings A/S (“Novo Holdings”) today announced…

Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…

Novo Nordisk Foundation announces an international open call for research projects to address key global challenges

As part of its Global Science Summit, the Novo Nordisk Foundation…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.